Less than a week later, Roche announced positive topline results from two arms of an ongoing, multi-part, phase I clinical trial for CT-996, an investigational, once-daily, oral GLP-1 receptor agonist being developed for the treatment of both Type 2 diabetes and obesity
If you are concerned about your relationship with food in the context of GLP-1 medication use, getting specialist input early is always the right approach
As best as we can tell from the research, it seems like that's not a major risk with these drugs
Not only were my own doctors and a GLP-1 expert seemingly receptive to a patient like me trying one, but few of the women I spoke with mentioned major side effects
In the United States, Tirzepatide has recently gained approval for treating moderate to severe obstructive sleep apnea in adults with obesity [119] as well as semaglutide use for metabolic dysfunctionassociated steatohepatitis (MASH) with moderatetoadvanced fibrosis [120]
